Straits Times Index
3,324.06 -2.22 (-0.07%) Nikkei
39,667.07 +493.92 (+1.26%) Hang Seng
18,079.08 +6.18 (+0.03%) FTSE 100
8,276.62 +28.83 (+0.35%) Bitcoin USD
61,727.59 +911.98 (+1.50%) CMC Crypto 200
1,280.99 -2.79 (-0.22%)
Amplify Weight Loss Drug & Treatment ETF (THNR)
| Previous close | 26.18 |
| Open | 26.41 |
| Bid | 25.31 x 900 |
| Ask | 39.51 x 800 |
| Day's range | 26.31 - 26.43 |
| 52-week range | 24.92 - 26.43 |
| Volume | |
| Avg. volume | 10,265 |
| Net assets | 1.52M |
| NAV | 26.16 |
| PE ratio (TTM) | N/A |
| Yield | N/A |
| YTD daily total return | N/A |
| Beta (5Y monthly) | 0.00 |
| Expense ratio (net) | 0.59% |
| Inception date | 2024-05-20 |
GlobeNewswireAmplify ETFs Earns Four Nominations for With Intelligence Mutual Fund and ETF Awards
Innovative ETF provider recognized for their industry leadership and creativityCHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs, a leading provider of innovative exchange-traded funds, is proud to announce its nominations in four categories at this year's With Intelligence Mutual Fund and ETF Awards. Amplify funds are being recognized in the following categories: ETF Innovation of the Year: Amplify Samsung SOFR ETF (SOF) - the first ETF aimed to deliver the closely-watched Secured Overnig
- GlobeNewswire
Amplify ETFs Launches The Amplify Weight Loss Drug & Treatment ETF (THNR)
THNR invests in companies at the forefront of GLP-1 innovationCHICAGO, May 21, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs announces the launch of the Amplify Weight Loss Drug & Treatment ETF (NYSE: THNR), an index-based ETF offering access to companies at the forefront of developing and marketing GLP-1 treatments. Over one billion individuals across the globe are now clinically obese, drawing significant attention to the obesity epidemic as a critical public health issue.1 With the rising global focu
